INSPIREMD INC. - COMMO

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

07 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

16 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

06 أغسطس 2024 08:09:23 بحسب Nasdaq GlobeNewswire

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

05 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

30 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

01 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024  

28 مايو 2024 08:53:00 بحسب Nasdaq GlobeNewswire

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

14 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

07 مايو 2024 07:00:01 بحسب Nasdaq GlobeNewswire

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

03 أبريل 2024 08:59:14 بحسب Nasdaq GlobeNewswire

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

26 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

06 مارس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

28 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

12 فبراير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework

31 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

03 يناير 2024 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

20 ديسمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

27 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

06 نوفمبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

InspireMD to Participate in Upcoming November Investor Conferences

02 نوفمبر 2023 08:00:01 بحسب Nasdaq GlobeNewswire